Archived Content
Day 1 | Day 2
Wednesday, November 7
8:00am Interactive Breakout Discussions
Concurrent breakout discussion groups are interactive, guided discussions hosted by a facilitator or set of co-facilitators to discuss some of the key issues presented earlier in the day’s sessions. Delegates will join a table of interest to them and become an active part of the discussion at hand.
Topics include:
Modern Clinical trials for DiagnosticsCatherine A. Schnabel, Ph.D., Senior Director, Medical & Scientific Affairs, bioTheranostics, Inc.
Reimbursement of Companion DiagnosticsEster Stein, MBA, Director, Corporate Reimbursement and Government Affairs, Abbott Molecular
CPT Code Warm UpKarl Florence, Director of Reimbursement, Vermillion
8:50am Chairperson’s Opening RemarksDanielle Scelfo, Director, Government Affairs, Genomic Health - Click here to watch an interview with Danielle Scelfo
9:00 • 2012 – A Tipping Point for the Industry: Coverage Coding and Reimbursement in Advanced Molecular Diagnostics
Danielle Scelfo, Director, Government Affairs, Genomic Health - Click here to watch an interview with Danielle Scelfo
9:30 CPT Code Application-The New Reality of a CPT Code Change
Karl Florence, Director of Reimbursement, Vermillion
This session will describe steps for a successful new Category I Multi Analyte Assay with Algorithmic Analysis (MAAA) Application. What are key questions in the application, what supporting documents are required, what publications and evidence are required, what levels of utilization or volume are needed, and types of professional support needed. Lastly, should you go it alone or with a consultant.
10:00 Sponsored Presentation (Opportunity Available)
10:30 Coffee Break in Exhibit Hall
11:00 Coding and Reimbursement for Molecular Testing: New Developments and Interesting Times Ahead
Roger D. Klein, M.D., J.D., Pathologist, Department of Molecular Pathology, Cleveland Clinic Foundation
11:30 Next-Generation Sequencing and the Reimbursement Landscape
Laura Sullivan, Vice President, Customer Care & Reimbursement, Good Start Genetics
New technology and changes to our CPT coding system have made the reimbursement landscape more challenging for the lab industry. Understanding how to navigate the coding structure is an important step when using Next Generation Sequencing to determine what your reimbursement may be for targeted sequencing as well as full sequencing.
12:00 Panel Discussion: The Good and the Bad of CPT Code ChangeModerated by Danielle Scelfo, Director, Government Affairs, Genomic Health
12:45pm End of Generating Evidence for Reimbursement Decisions: Diagnostics
Day 1 | Day 2